![]() Vita 34 Vita 34 is the largest and the most experienced umbilical cord blood bank for medical precaution by means of stem cells in the German-speaking countries. | |||||
Founding Date | Founding Date 1998 | Founding Date 1976 | Founding Date 1990 | Founding Date 1997 | Founding Date 2000 |
Type | Type Private | Type Subsidiary | Type Public | Type Public | Type Private |
Tags | |||||
Locations | Locations Ajdovščina, SI HQ | Locations Minneapolis, US HQ Oakville, CA Toronto, CA Shanghai, CN Shanghai, CN Hong Kong, HK Abingdon, GB | Locations Stockholm, SE HQ Hiroshima Shi, JP Minato Ku, JP Singapore, SG Lund, SE Doral, US | Locations Leipzig, DE HQ Leipzig, DE | Locations Memphis, US HQ |
Employees | Employees 488% decrease | Employees 605 | Employees 167 | Employees 771 | Employees 1391% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 1 b | Valuation ($) 77.9 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) kr1.5b (FY, 2025) | Revenue (est.) €88.2m (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods kr391m (FY, 2025) | Cost of goods €30m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit kr1.1b (FY, 2025) | Gross profit €59.8m (FY, 2025) | Gross profit N/A |
Net income | Net income N/A | Net income N/A | Net income kr332.8m (FY, 2025) | Net income (€5m) (FY, 2025) | Net income N/A |

R&D Systems is a company that produces and markets biological solutions.
View company
BioGaia is a biotechnology company that develops and sells probiotic solutions.
View company
Vita 34 is the largest and the most experienced umbilical cord blood bank for medical precaution by means of stem cells in the German-speaking countries.
View companyTransnetyx is a provider of biotechnology solutions.
View company